Echo Therapeutics (ECTE) 2.02 $ECTE
Platinum Delivers Letter To Echo Therapeutics, Inc. Demanding To Inspect Certain Books And Records Under Delaware Law
PR Newswire - Wed Jul 23, 6:44PM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum"
has delivered a letter to Echo pursuant to Section 220 of the Delaware General Corporation Law demanding to inspect certain books and records of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) relating to possible mismanagement, breaches of fiduciary duty and wrongdoing by, among others, members of the Board and the Company's current interim CEO, Kimberly A. Burke. Platinum, together with certain of its affiliates, is the largest stockholder of the Company owning approximately 30% of the outstanding Common Stock on a fully converted basis.
Platinum Reports On Town Hall Meeting For Echo Therapeutics, Inc. Stockholders
PR Newswire - Tue Jul 22, 10:26AM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum" , which beneficially hold approximately 30.34% of the shares of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) on a fully converted basis, today reported on the Town Hall Meeting it recently hosted for the concerned stockholders of Echo. All Company directors and stockholders were invited to attend the Town Hall Meeting, but sadly directors Vincent D. Enright, William F. Grieco and James F. Smith (the "Lingering Directors" did not participate despite the dire need for immediate change at Echo.
Disturbing Self-Dealing By Repudiated Echo Directors Forces Platinum To Exercise Contractual Right To Call Special Meeting; Town Hall Meeting Also Planned
PR Newswire - Thu Jul 10, 4:14PM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum" , the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or the "Company" owning approximately 20% of the Company's outstanding Common Stock, sent a letter to the Company today exercising Platinum's contractual right under the December 10, 2013 Stock Purchase Agreement between Platinum and the Company to cause Echo to call a meeting of stockholders to vote to lift the "blockers" limiting Platinum's voting power.
Echo Announces Election Of New Board Member At Annual Meeting Of Stockholders
PR Newswire - Thu Jun 19, 3:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that, based on preliminary results provided by Echo's proxy solicitor, stockholders have elected Shepard M. Goldberg as a new member of the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. These preliminary results are subject to receipt of the official confirmation by the independent inspector of elections, IVS Associates, Inc., which is expected to be received early next week.
Echo Mails Letter To Stockholders
PR Newswire - Wed Jun 11, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is mailing a letter to its stockholders urging them to follow the recommendations of the three leading independent proxy advisory firms and vote only the WHITE proxy card to ensure that Echo's highly qualified and very experienced director and Interim CEO, Robert F. Doman, is re-elected to the Echo Board.
Platinum Releases Statement on Echo Therapeutics Upcoming Annual Meeting
PR Newswire - Tue Jun 10, 10:25AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc., (NasdaqCM: ECTE) ("Echo" or "Company" owning approximately 20% of the common stock, issued the following statement regarding the upcoming June 19th annual meeting of Echo stockholders:
Leading Independent Proxy Advisory Firm Egan-Jones Joins ISS And Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card
PR Newswire - Mon Jun 09, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Egan-Jones Proxy Services, a leading independent proxy advisory firm, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. Egan-Jones' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to Echo's highly qualified and very experienced director and Interim CEO, Robert F. Doman. With Egan-Jones, ISS and Glass Lewis making the same recommendation, all three of the leading independent proxy advisory firms have now advised Echo's stockholders to support the Echo Board's nominees and reject the Platinum Group's nominee, Shepard Goldberg.
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card
PR Newswire - Fri Jun 06, 2:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that ISS Proxy Advisory Services, a leading independent proxy advisory firm, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. ISS' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to our highly qualified and very experienced director and Interim CEO, Robert F. Doman. With ISS and Glass Lewis making the same recommendation, both of the leading proxy advisory firms have now advised Echo's stockholders to support the Echo Board's nominees and reject the Platinum Group's nominee, Shepard Goldberg.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Stockholders Vote The WHITE Proxy Card FOR Echo's Board Nominees
PR Newswire - Thu Jun 05, 3:17PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Glass Lewis & Co., a leading independent proxy advisory service, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR both of the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. Glass Lewis' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to our highly qualified and very experienced director and Interim CEO, Robert F. Doman.
Positive Clinical Trial Results of Echo Therapeutics Symphony CGM System to be Presented at the 74th Scientific Sessions of the American Diabetes Association
PR Newswire - Thu Jun 05, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA.
Platinum Management (NY) LLC Files Investor Presentation in Connection with the June 19th Annual Meeting of Echo Therapeutics, Inc. Stockholders
PR Newswire - Fri May 30, 11:55AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc., (NasdaqCM: ECTE) ("Echo" or "Company" owning approximately 20% of the common stock, announced today that it has filed an investor presentation detailing the case for change at Echo. Echo stockholders are strongly encouraged to view the investor presentation and Platinum's other communications with Echo stockholders at www.morrowco.com/platinum or at the SEC website, www.sec.gov.
Echo Therapeutics to File Investor Presentation
PR Newswire - Fri May 30, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is filing an investor presentation with the U.S. Securities and Exchange Commission (SEC) that comments on, among other things, the pending proxy contest by a dissident stockholder group led by Platinum Management (NY) LLC. The presentation will be available later today on the Investor Relations section of Echo's website at http://www.echotx.com and on the SEC's website at www.sec.gov.
Platinum Management (NY) LLC Mails Letter to Stockholders of Echo Therapeutics, Inc.
PR Newswire - Thu May 29, 2:02PM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or "The Company" owning approximately 20% of the common stock, announced today that it has mailed a letter to stockholders of Echo urging them to vote the GOLD proxy card or GOLD voting instruction form in favor of Platinum's nominee, Shepard Goldberg, at the Company's upcoming Annual Meeting of stockholders scheduled for June 19th, 2014. Stockholders are urged to not vote Echo's white proxy card to withhold on Robert Doman, as that is not the same as voting for Platinum's nominee on the GOLD card. Only the latest dated card counts.
Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo" , a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium.
Platinum Delivers Letter To Echo Therapeutics, Inc. Demanding To Inspect Certain Books And Records Under Delaware Law
PR Newswire - Wed Jul 23, 6:44PM CDT
An affiliate of Platinum Management (NY) LLC ("Platinum"
has delivered a letter to Echo pursuant to Section 220 of the Delaware General Corporation Law demanding to inspect certain books and records of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) relating to possible mismanagement, breaches of fiduciary duty and wrongdoing by, among others, members of the Board and the Company's current interim CEO, Kimberly A. Burke. Platinum, together with certain of its affiliates, is the largest stockholder of the Company owning approximately 30% of the outstanding Common Stock on a fully converted basis. Platinum Reports On Town Hall Meeting For Echo Therapeutics, Inc. Stockholders
PR Newswire - Tue Jul 22, 10:26AM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum"
, which beneficially hold approximately 30.34% of the shares of Echo Therapeutics, Inc. ("Echo" or the "Company" (NASDAQ: ECTE) on a fully converted basis, today reported on the Town Hall Meeting it recently hosted for the concerned stockholders of Echo. All Company directors and stockholders were invited to attend the Town Hall Meeting, but sadly directors Vincent D. Enright, William F. Grieco and James F. Smith (the "Lingering Directors" did not participate despite the dire need for immediate change at Echo. Disturbing Self-Dealing By Repudiated Echo Directors Forces Platinum To Exercise Contractual Right To Call Special Meeting; Town Hall Meeting Also Planned
PR Newswire - Thu Jul 10, 4:14PM CDT
Platinum Management (NY) LLC and certain affiliates ("Platinum"
, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or the "Company" owning approximately 20% of the Company's outstanding Common Stock, sent a letter to the Company today exercising Platinum's contractual right under the December 10, 2013 Stock Purchase Agreement between Platinum and the Company to cause Echo to call a meeting of stockholders to vote to lift the "blockers" limiting Platinum's voting power. Echo Announces Election Of New Board Member At Annual Meeting Of Stockholders
PR Newswire - Thu Jun 19, 3:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that, based on preliminary results provided by Echo's proxy solicitor, stockholders have elected Shepard M. Goldberg as a new member of the Echo Board of Directors at the 2014 Annual Meeting of Stockholders held on Thursday, June 19, 2014. These preliminary results are subject to receipt of the official confirmation by the independent inspector of elections, IVS Associates, Inc., which is expected to be received early next week.
Echo Mails Letter To Stockholders
PR Newswire - Wed Jun 11, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is mailing a letter to its stockholders urging them to follow the recommendations of the three leading independent proxy advisory firms and vote only the WHITE proxy card to ensure that Echo's highly qualified and very experienced director and Interim CEO, Robert F. Doman, is re-elected to the Echo Board.
Platinum Releases Statement on Echo Therapeutics Upcoming Annual Meeting
PR Newswire - Tue Jun 10, 10:25AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc., (NasdaqCM: ECTE) ("Echo" or "Company"
owning approximately 20% of the common stock, issued the following statement regarding the upcoming June 19th annual meeting of Echo stockholders: Leading Independent Proxy Advisory Firm Egan-Jones Joins ISS And Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card
PR Newswire - Mon Jun 09, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Egan-Jones Proxy Services, a leading independent proxy advisory firm, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. Egan-Jones' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to Echo's highly qualified and very experienced director and Interim CEO, Robert F. Doman. With Egan-Jones, ISS and Glass Lewis making the same recommendation, all three of the leading independent proxy advisory firms have now advised Echo's stockholders to support the Echo Board's nominees and reject the Platinum Group's nominee, Shepard Goldberg.
Leading Independent Proxy Advisory Firm ISS Joins Glass Lewis In Recommending That Echo Stockholders Reject Platinum's Board Nominee Shepard Goldberg And Vote The WHITE Proxy Card
PR Newswire - Fri Jun 06, 2:07PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that ISS Proxy Advisory Services, a leading independent proxy advisory firm, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. ISS' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to our highly qualified and very experienced director and Interim CEO, Robert F. Doman. With ISS and Glass Lewis making the same recommendation, both of the leading proxy advisory firms have now advised Echo's stockholders to support the Echo Board's nominees and reject the Platinum Group's nominee, Shepard Goldberg.
Leading Independent Proxy Advisory Firm Glass Lewis Recommends That Stockholders Vote The WHITE Proxy Card FOR Echo's Board Nominees
PR Newswire - Thu Jun 05, 3:17PM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that Glass Lewis & Co., a leading independent proxy advisory service, has recommended to its clients that Echo stockholders vote the WHITE proxy card FOR both of the Echo Board of Directors' director nominees at Echo's Annual Meeting of Stockholders to be held on June 19, 2014. Glass Lewis' clients include institutional investors, mutual funds, pension funds and other fiduciaries. As previously announced, the Platinum Group, a dissident stockholder group led by Platinum Management (NY) LLC, is pursuing a proxy contest to elect Shepard M. Goldberg to the Echo Board at Echo's 2014 Annual Meeting in opposition to our highly qualified and very experienced director and Interim CEO, Robert F. Doman.
Positive Clinical Trial Results of Echo Therapeutics Symphony CGM System to be Presented at the 74th Scientific Sessions of the American Diabetes Association
PR Newswire - Thu Jun 05, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its most recently completed clinical study of Symphony was selected for poster presentation at the 74th Scientific Sessions of the American Diabetes Association (ADA) which will be held June 13-17, 2014 in San Francisco, CA. Platinum Management (NY) LLC Files Investor Presentation in Connection with the June 19th Annual Meeting of Echo Therapeutics, Inc. Stockholders
PR Newswire - Fri May 30, 11:55AM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc., (NasdaqCM: ECTE) ("Echo" or "Company"
owning approximately 20% of the common stock, announced today that it has filed an investor presentation detailing the case for change at Echo. Echo stockholders are strongly encouraged to view the investor presentation and Platinum's other communications with Echo stockholders at www.morrowco.com/platinum or at the SEC website, www.sec.gov. Echo Therapeutics to File Investor Presentation
PR Newswire - Fri May 30, 6:50AM CDT
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it is filing an investor presentation with the U.S. Securities and Exchange Commission (SEC) that comments on, among other things, the pending proxy contest by a dissident stockholder group led by Platinum Management (NY) LLC. The presentation will be available later today on the Investor Relations section of Echo's website at http://www.echotx.com and on the SEC's website at www.sec.gov.
Platinum Management (NY) LLC Mails Letter to Stockholders of Echo Therapeutics, Inc.
PR Newswire - Thu May 29, 2:02PM CDT
Platinum Management (NY) LLC and certain affiliates, the largest stockholder of Echo Therapeutics, Inc. (NasdaqCM: ECTE) ("Echo" or "The Company"
owning approximately 20% of the common stock, announced today that it has mailed a letter to stockholders of Echo urging them to vote the GOLD proxy card or GOLD voting instruction form in favor of Platinum's nominee, Shepard Goldberg, at the Company's upcoming Annual Meeting of stockholders scheduled for June 19th, 2014. Stockholders are urged to not vote Echo's white proxy card to withhold on Robert Doman, as that is not the same as voting for Platinum's nominee on the GOLD card. Only the latest dated card counts. Echo Therapeutics, Inc. Announces 2013 Financial Results
PR Newswire - Thu Mar 27, 6:50AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013. Echo's Annual Report on Form 10-K, as filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com on March 28, 2014 after the close of the financial markets.
Echo Therapeutics Schedules 2013 Financial Results for Thursday, March 27, 2014
PR Newswire - Thu Mar 20, 8:35AM CDT
Echo Therapeutics, Inc. (Nasdaq: ECTE), a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced that it will release financial results for the year ended December 31, 2013 on Thursday, March 27, 2014. Management will hold a conference call to review the company's 2013 performance starting at 9:00 a.m. ET on the same day.
4 Stocks Under $10 Making Big Moves
at The Street - Mon Mar 17, 6:46AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
Echo Therapeutics to Exhibit at the ISICEM 2014 Critical Care Conference
PR Newswire - Thu Mar 06, 6:50AM CST
Echo Therapeutics, Inc. (Nasdaq: ECTE) ("Echo"
, a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, is pleased to announce that its clinical study of Symphony was selected for poster presentation at the 34th International Symposium on Intensive Care and Emergency Medicine (ISICEM) from March 18-21, 2014 in Brussels, Belgium. 
